Hi - would greatly appreciate any scientists//physicists/medical practitioners who are really knowledgeable in this field (both theoretical but more importantly practical experience).
1. Pros and Cons of Carrier vs Non-Carrier (ie. SLX process is focused on indirect method non-carrier production of LU-177 via production of YB-176). So just trying to understand which of Carrier vs Non-Carrier is a better/more efficient process. (Goes to viability of this opportunity set).
2. Indirect NCA from what i read still leaves impurities of YB-176 in the LU-177 (5000:1?). (a) Is this true and (b) is the level of impurity material from a medical/treatment standpoint?
I'm just a layman trying to understand the opportunity set of MIST for SLX. the nuclear side of SLX is well covered and now starting to take-off - so just would like to understand more about MIST (and separately later the QC side of SLX)
Cheers
SLX Price at posting:
$3.28 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)